Olink at the 2022 European Society for Human Genetics (ESHG) Conference

This year’s ESHG conference will be held June 11-14, 2022 in Vienna, Austria as both an in-person as well as virtual event; here are a few highlighted talks of interest as it relates to the combination of genetics, proteomics and other multiomic strategies for personalized medicine

Presentations at ESHG of interest

At this human genetics conference, several presentations will touch upon proteomics as part of a larger multiomic strategy for either identification of potential diagnostic markers of disease or insight into disease mechanism through combining genomic variation data with circulating protein biomarker information.

To underscore the future potential of protein analysis at a genetics conference, an opening keynote plenary session (Saturday 11 June 2022, 1400 to 1630 CET, session PL1.3) from Dr. John Jumper of the Google’s AlphaFold project will present on “Highly accurate protein structure prediction and its implications for understanding human biology”.

Regarding the potential for protein biomarkers as part of a multi-omic approach to development of disease diagnostics, one presentation will be made in a concurrent session (Sunday 12 June 2022, 1030-1230 CET, session C11) called “Rapid rare disease diagnosis on a national scale: an integrated multi-omic approach” from Dr. Zornitza Stark of Victorian Clinical Genetics Services, Royal Children’s Hospital, Victoria Australia. A second presentation (Monday 13 June 2022, 0830-1000 CET, session S12.3) called “Deciphering the genomic aetiology of osteoarthritis” will be presented by Dr. Eleftheria Zeggini from the Technical University of Munich, in a concurrent symposia titled “Genetics of Omics and Beyond”.

Dr. Kari Steffanson, CEO of deCODE Genetics

Dr. Kari Steffanson, CEO of deCODE Genetics, will present an Olink-sponsored talk (Sunday 12 June 2022, 1200-1300 CET, Room M 1+2) on the topic “The Proteome as a net with which to catch environmental influences on phenotypes”.

An Olink Poster about combining PEA with NGS

On Sunday 12 June 2022 1600-1700 CET Dr. Cindy Lawley, Olink Director of Population Health, will present a poster titled “Proximity extension assay in combination with Next-Generation Sequencing for high-throughput proteome-wide analysis in large population health studies” in the Poster Hall section X3.

If you are attending ESHG in 2022 in-person, come by booth number 152 and we would love to speak with you.

European Society for Human Genetics 2022 Conference

How the proteome behaves in healthy individuals

Clinical research, Multiomics
To achieve the goal of precision medicine, not only do different molecular profiles need to be understood in disease populations, but they must also be understood in the context of healthy populations.

Key proteomics publications from 2020

Proteomics
Welcome to the first post of the all-new weekly Olink to Science! Our customer survey revealed that you would like to know more about the many publications, research, and other science happening at Olink, therefore this blog aims to do just that: keep you informed on the exciting science taking place with our technology.

Protein biomarkers are crucial in early detection of cancer

Clinical research, Oncology, Protein biomarkers
A central premise of precision medicine is to identify biomarkers indicative of disease transitions early on. This is especially important in cancer where early treatment intervention could increase a patient’s chance of survival and reduce the probability of cancer recurrence.

Using PEA and RNA-Seq to study disease pathology

Clinical research, Proteomics
The following study illustrates how transcriptomics and proteomics complement one another to clarify the pathology of a complex, and little understood disease. Atopic dermatitis (AD) is the most common chronic skin condition affecting up to 20% of children and 7-10% of adults, depending on the population.

Olink protein biomarker panel indicates fermented foods fight inflammation

Inflammation, Proteomics
Could food be used to fight chronic disease?

Study identifies proteins involved in immunotherapy response

Oncology, Proteomics
'Ultimately, it is all about understanding and treating patients better in the future.'

Proteins diagnostic of lung cancer up to 5 years before disease onset

Oncology
An earlier Olink to Science blog post covered some amazing research that found that certain blood protein biomarkers have the potential to predict cancer up to 3 years before diagnosis. This may also be the case for lung cancer, as detailed in a recent study by Dagnino and her colleagues, where elevated levels of CDCP1 were detected in participants of a cohort who later developed the disease.

Utilizing proteogenomics technology for novel drug target discovery

Drug discovery & development
High-throughput multiplexed proteomic technology is leading the way to the latest developments in pre-clinical disease analysis in drug discovery. The pharmaceutical industry is now increasing its efforts in the discovery of novel drug targets by using protein quantitative trait loci (pQTLs), which allows for a more confident inference of disease causality and associated protein regulation.

Developing a high-performance biomarker panel for Alzheimer’s disease

Clinical research, Neurology, Protein biomarkers
A simple search of the term ‘scourge of Alzheimer’s Disease’ brings up over half a million website hits. A major disease, about 15% of us that reach the age of 67 to 74, and 44% of those 75 to 84 will develop AD.

How proteomics helped diabetic kidney disease research advance

Clinical research, Proteomics
Dr. Krolewski and his team at the Harvard Medical School found 56 proteins to be significant in diabetic kidney disease patients. Potentially, these could serve as prognostic biomarkers for disease progression and treatment response. This is how adding proteomics to the methodologies elevated their research.

2947

Biomarker assays

~881 million

Protein data points generated

1182

Publications listed on website